NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
50.44
+0.63 (+1.26%)
At close: 4:04PM EDT

50.70 +0.26 (0.52%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous close49.81
Open50.16
Bid0.00 x 0
Ask0.00 x 0
Day's range50.11 - 50.63
52-week range41.03 - 58.37
Volume1,378,900
Avg. volume1,624,480
Market cap122.112B
Beta0.82
PE ratio (TTM)20.52
EPS (TTM)2.46
Earnings dateN/A
Forward dividend & yield1.28 (2.63%)
Ex-dividend date2018-03-23
1y target est60.40
Trade prices are not sourced from all markets
  • LLY vs. NVO: Which Stock Is the Better Value Option?
    Zacksyesterday

    LLY vs. NVO: Which Stock Is the Better Value Option?

    LLY vs. NVO: Which Stock Is the Better Value Option?

  • Drugmakers Cancel Price Hikes After California Law Takes Effect
    Bloomberg10 days ago

    Drugmakers Cancel Price Hikes After California Law Takes Effect

    A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.

  • Top Stocks Set to Disrupt the Diabetes Market
    Motley Fool14 days ago

    Top Stocks Set to Disrupt the Diabetes Market

    Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.

  • A Look at Novo Nordisk’s Biopharmaceuticals
    Market Realist16 days ago

    A Look at Novo Nordisk’s Biopharmaceuticals

    In the first quarter, Novo Nordisk’s (NVO) Hemophilia segment generated net revenues of 2.5 billion Danish kroner compared to 2.58 billion Danish kroner in the first quarter of 2017, reflecting ~3.0% YoY (year-over-year) growth.

  • NVO’s Victoza and Ozempic Could See Steady Growth in 2018
    Market Realist16 days ago

    NVO’s Victoza and Ozempic Could See Steady Growth in 2018

    Novo Nordisk’s (NVO) Victoza generated revenues of 5.99 billion Danish kroner in the first quarter, compared to 5.75 billion Danish kroner in the first quarter of 2017, reflecting ~4.0% YoY (year-over-year) growth.

  • The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin
    Market Realist16 days ago

    The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin

    In the first quarter, Novo Nordisk’s (NVO) premix insulin generated net revenues of 2.64 billion Danish kroner compared to 2.86 billion Danish kroner in the first quarter of 2017, which reflected an ~8.0% YoY (year-over-year) decline.

  • NVO’s Tresiba and Xultophy Could See Solid Growth in 2018
    Market Realist17 days ago

    NVO’s Tresiba and Xultophy Could See Solid Growth in 2018

    Novo Nordisk’s (NVO) Tresiba reported revenues of 1.76 billion Danish kroner in the first quarter compared to 1.49 billion Danish kroner in the first quarter of 2017, which reflected ~18.0% YoY (year-over-year) growth.

  • Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver
    Market Realist17 days ago

    Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

    In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial. This trial demonstrated that oral semaglutide significantly decreased the blood sugar levels in individuals with type 2 diabetes compared to placebo therapy.

  • A Look at Novo Nordisk’s Financial Position
    Market Realist17 days ago

    A Look at Novo Nordisk’s Financial Position

    Novo Nordisk (NVO) reported revenues of 26.9 billion Danish kroner in the first quarter, compared to 28.5 billion Danish kroner in the first quarter of 2017, which reflected an ~5.0% year-over-year (or YoY) decline.

  • GlobeNewswire25 days ago

    EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr. Ando, the former Chairman of the Board of Novo Nordisk A/S (NVO), a global pharmaceutical company, brings more than 35 years of global drug development and general management experience to EyePoint. “Dr. Ando’s extensive experience across the many facets of the global pharmaceutical industry will undoubtedly be valuable as we transition into a commercial ophthalmic company with our planned U.S. launches of DEXYCU™ and, if approved, YUTIQ™,” said David J. Mazzo, Ph.D., Chairman of the Board of Directors of EyePoint Pharmaceuticals.

  • Novo Nordisk (NVO) Announces Results in Diabetes Studies
    Zacks25 days ago

    Novo Nordisk (NVO) Announces Results in Diabetes Studies

    Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

  • 5 Biggest Blockbuster Diabetes Drugs of the Future
    Motley Fool27 days ago

    5 Biggest Blockbuster Diabetes Drugs of the Future

    The diabetes market is growing rapidly. These drugs -- and drugmakers -- should be the biggest winners.

  • Bloomberg27 days ago

    Novo Says Tresiba Shows Significantly Better Blood Sugar Control

    Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study....

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks28 days ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
    Zacks29 days ago

    Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

    Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

  • Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
    Zackslast month

    Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

    Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

  • LLY vs. NVO: Which Stock Should Value Investors Buy Now?
    Zackslast month

    LLY vs. NVO: Which Stock Should Value Investors Buy Now?

    LLY vs. NVO: Which Stock Is the Better Value Option?

  • Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
    Motley Foollast month

    Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming

    Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?

  • Analyzing Novartis’s Revenue in Q1
    Market Realist2 months ago

    Analyzing Novartis’s Revenue in Q1

    In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.

  • Top Diabetes Stocks to Buy Today
    Motley Fool2 months ago

    Top Diabetes Stocks to Buy Today

    More people than ever are being diagnosed with diabetes, and big advances in treatment could make these diabetes stocks savvy investments.

  • GlobeNewswire2 months ago

    Emisphere Development Update

    ROSELAND, N.J., May 31, 2018-- Novo Nordisk announced Tuesday the completion of the second phase 3 a trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog ...

  • Novo Nordisk's Oral Ozempic Positive in Diabetes Study
    Zacks2 months ago

    Novo Nordisk's Oral Ozempic Positive in Diabetes Study

    Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

  • How to Invest in Diabetes Stocks
    Motley Fool2 months ago

    How to Invest in Diabetes Stocks

    Here's everything you need to know about investing in the fast-growing diabetes market.

  • MarketWatch2 months ago

    Almost a quarter of the world’s population will be obese by 2045

    Obesity is a global epidemic. Nearly one-quarter (22%) of the people in the world will be obese by 2045, up from 14% in 2017, and one in eight will have type 2 diabetes, up from 9% in 2017, it concluded. Using a World Health Organization database and dividing each country’s population into age groups, the authors suggest that — in order to stabilize the rate of global diabetes at 10% — obesity rates must fall from the current level of 14% to 10% by 2045.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within El Pollo Loco, Chemed, Novo Nordisk A/S, FactSet Research, Fair Isaac, and HCP — Future Expectations, Projections Moving into 2018

    NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of El ...